Welcome to our dedicated page for Lobe Sciences Ltd. news (Ticker: $LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lobe Sciences Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lobe Sciences Ltd.'s position in the market.
Lobe Sciences (OTCQB: LOBEF) and Clearway Global have announced a change of control, with Clearway gaining voting control of Lobe.
This follows Lobe's acquisition of Altemia & Company, resulting in Clearway owning 52.69% of Lobe's shares. The companies aim to enhance growth strategies, including appointing new board members, securing funding, and addressing accounts payable.
Lobe has issued 16,424,220 shares to Clearway under a consulting agreement. The focus will be on Lobe’s L-130, an oral Psilocin-based drug, with plans for an investor communications program to share recent trial data and unlock shareholder value. The Annual General Meeting is scheduled for July 22, 2024.